- Home
- Publications
- Publication Search
- Publication Details
Title
Gene-based therapies for neurodegenerative diseases
Authors
Keywords
-
Journal
NATURE NEUROSCIENCE
Volume 24, Issue 3, Pages 297-311
Publisher
Springer Science and Business Media LLC
Online
2021-02-02
DOI
10.1038/s41593-020-00778-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer’s Disease Identifies a Need for Improved Vector Delivery
- (2020) Michael J. Castle et al. HUMAN GENE THERAPY
- Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial
- (2020) Suryanarayan Somanathan et al. MOLECULAR THERAPY
- The promise and challenge of therapeutic genome editing
- (2020) Jennifer A. Doudna NATURE
- Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses
- (2020) Jonathan M. Levy et al. Nature Biomedical Engineering
- A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects
- (2020) Erwei Zuo et al. NATURE METHODS
- Antisense oligonucleotides for neurodegeneration
- (2020) Blair R. Leavitt et al. SCIENCE
- ORANGE: A CRISPR/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons
- (2020) Jelmer Willems et al. PLOS BIOLOGY
- Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
- (2020) James M. Wilson et al. HUMAN GENE THERAPY
- Reversing a model of Parkinson’s disease with in situ converted nigral neurons
- (2020) Hao Qian et al. NATURE
- SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
- (2020) Christian Mueller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
- (2020) Timothy Miller et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALS Genetics: Gains, Losses, and Implications for Future Therapies
- (2020) Garam Kim et al. NEURON
- Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
- (2019) Morgan L. Maeder et al. NATURE MEDICINE
- Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
- (2019) Eloise Hudry et al. NEURON
- Magnetic Resonance Imaging–Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease
- (2019) Chadwick W. Christine et al. ANNALS OF NEUROLOGY
- RNA-Guided Adenosine Deaminases: Advances and Challenges for Therapeutic RNA Editing
- (2019) Genghao Chen et al. BIOCHEMISTRY
- Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
- (2019) Julian Grünewald et al. NATURE
- Precise therapeutic gene correction by a simple nuclease-induced double-stranded break
- (2019) Sukanya Iyer et al. NATURE
- The next generation of CRISPR–Cas technologies and applications
- (2019) Adrian Pickar-Oliver et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nusinersen in later-onset spinal muscular atrophy
- (2019) Basil T. Darras et al. NEUROLOGY
- Targeting Huntingtin Expression in Patients with Huntington’s Disease
- (2019) Sarah J. Tabrizi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON’S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA’S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES
- (2019) Kevin McFarthing et al. Journal of Parkinsons Disease
- Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
- (2019) Bryan Zeitler et al. NATURE MEDICINE
- Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
- (2019) Yu Yamazaki et al. Nature Reviews Neurology
- Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease
- (2019) So Hyun Park et al. NUCLEIC ACIDS RESEARCH
- A cytosine deaminase for programmable single-base RNA editing
- (2019) Omar O. Abudayyeh et al. SCIENCE
- Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa
- (2019) Cia-Hin Lau et al. Molecular Therapy-Nucleic Acids
- An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
- (2019) Basil T. Darras et al. CNS DRUGS
- Glucocerebrosidase and its relevance to Parkinson disease
- (2019) Jenny Do et al. Molecular Neurodegeneration
- Search-and-replace genome editing without double-strand breaks or donor DNA
- (2019) Andrew V. Anzalone et al. NATURE
- TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
- (2019) Scott N. Ashley et al. CELLULAR IMMUNOLOGY
- Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
- (2019) Natalie F. Nidetz et al. PHARMACOLOGY & THERAPEUTICS
- Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits
- (2018) Ramon Velazquez et al. AGING CELL
- Viral Strategies for Targeting the Central and Peripheral Nervous Systems
- (2018) Claire N. Bedbrook et al. Annual Review of Neuroscience
- Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
- (2018) Silvana Konermann et al. CELL
- MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates
- (2018) Alan H. Nagahara et al. GENE THERAPY
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
- (2018) Christian Hinderer et al. HUMAN GENE THERAPY
- Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells
- (2018) Miaojin Zhou et al. HUMAN GENE THERAPY
- Gene therapy clinical trials worldwide to 2017: An update
- (2018) Samantha L. Ginn et al. JOURNAL OF GENE MEDICINE
- Targeting Amyloid-β Precursor Protein, APP , Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β Production
- (2018) Jennifer L. Chang et al. MOLECULAR THERAPY
- AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model
- (2018) Melvin M. Evers et al. MOLECULAR THERAPY
- APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease Phenotypes in Human iPSC-Derived Brain Cell Types
- (2018) Yuan-Ta Lin et al. NEURON
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease
- (2018) Michael S. Rafii et al. JAMA Neurology
- Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
- (2018) Matthew J. Benskey et al. Frontiers in Molecular Neuroscience
- CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer’s Disease
- (2018) Bence György et al. Molecular Therapy-Nucleic Acids
- AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
- (2018) Jonathan B. Rosenberg et al. Human Gene Therapy Clinical Development
- Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD
- (2018) Boris Kantor et al. MOLECULAR THERAPY
- Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy
- (2018) Samiah Al‐Zaidy et al. PEDIATRIC PULMONOLOGY
- Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
- (2017) Eric Doran et al. JOURNAL OF ALZHEIMERS DISEASE
- AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy
- (2017) Giuseppe Morabito et al. MOLECULAR THERAPY
- RNA targeting with CRISPR–Cas13
- (2017) Omar O. Abudayyeh et al. NATURE
- Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
- (2017) Nicole M. Gaudelli et al. NATURE
- Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions
- (2017) Y Bill Kim et al. NATURE BIOTECHNOLOGY
- α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
- (2017) Yvette C Wong et al. NATURE MEDICINE
- Tau-based therapies in neurodegeneration: opportunities and challenges
- (2017) Chuanzhou Li et al. NATURE REVIEWS DRUG DISCOVERY
- Antisense oligonucleotides: the next frontier for treatment of neurological disorders
- (2017) Carlo Rinaldi et al. Nature Reviews Neurology
- Not just amyloid: physiological functions of the amyloid precursor protein family
- (2017) Ulrike C. Müller et al. NATURE REVIEWS NEUROSCIENCE
- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
- (2017) Jerry R. Mendell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
- (2017) Sarah L. DeVos et al. Science Translational Medicine
- Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis
- (2017) Paula Dietrich et al. PLoS Genetics
- LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
- (2017) Hien Tran Zhao et al. Molecular Therapy-Nucleic Acids
- In vivo genome editing improves motor function and extends survival in a mouse model of ALS
- (2017) Thomas Gaj et al. Science Advances
- Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine
- (2016) Maximilian W. Popp et al. CELL
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression
- (2016) Frank Soldner et al. NATURE
- Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
- (2016) Alexis C. Komor et al. NATURE
- The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease
- (2016) Aaron R. Haeusler et al. NATURE REVIEWS NEUROSCIENCE
- Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs
- (2016) Jie Jiang et al. NEURON
- Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis
- (2016) Guohao Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
- (2015) Romain Fol et al. ACTA NEUROPATHOLOGICA
- shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
- (2015) Alevtina D. Zharikov et al. JOURNAL OF CLINICAL INVESTIGATION
- Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway
- (2015) Utpal Das et al. NATURE NEUROSCIENCE
- Nerve Growth Factor Gene Therapy
- (2015) Mark H. Tuszynski et al. JAMA Neurology
- Apolipoprotein E in Alzheimer's Disease: An Update
- (2014) Jin-Tai Yu et al. Annual Review of Neuroscience
- Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
- (2014) Lisa M. Stanek et al. HUMAN GENE THERAPY
- Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- (2014) Stéphane Palfi et al. LANCET
- In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
- (2014) Amber L Southwell et al. MOLECULAR THERAPY
- SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
- (2014) N. A. Naryshkin et al. SCIENCE
- Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies
- (2014) Reeteka Sud et al. Molecular Therapy-Nucleic Acids
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS
- (2013) Kevin D Foust et al. MOLECULAR THERAPY
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
- (2013) R. T. Bartus et al. NEUROLOGY
- ClinVar: public archive of relationships among sequence variation and human phenotype
- (2013) Melissa J. Landrum et al. NUCLEIC ACIDS RESEARCH
- Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
- (2013) Daniel Ness et al. PLoS One
- Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
- (2013) Marco A. S. Baptista et al. PLoS One
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain
- (2013) E. Hudry et al. Science Translational Medicine
- Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
- (2012) Richard Grondin et al. BRAIN
- Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
- (2012) Gabriele Mittermeyer et al. HUMAN GENE THERAPY
- Ubiquitin-specific Protease 9x Deubiquitinates and Stabilizes the Spinal Muscular Atrophy Protein-Survival Motor Neuron
- (2012) Ke-Jun Han et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TALENs: a widely applicable technology for targeted genome editing
- (2012) J. Keith Joung et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
- (2012) Holly B. Kordasiewicz et al. NEURON
- Long-Term Follow-Up After Gene Therapy for Canavan Disease
- (2012) P. Leone et al. Science Translational Medicine
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum
- (2011) Waldy San Sebastian et al. HUMAN GENE THERAPY
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
- (2011) Peter A LeWitt et al. LANCET NEUROLOGY
- Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
- (2011) Jodi L McBride et al. MOLECULAR THERAPY
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS
- (2011) Mariely DeJesus-Hernandez et al. NEURON
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
- (2011) M. A. Passini et al. Science Translational Medicine
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Huntington's disease: from molecular pathogenesis to clinical treatment
- (2010) Christopher A Ross et al. LANCET NEUROLOGY
- In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
- (2010) Oleg S Gorbatyuk et al. MOLECULAR THERAPY
- Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains
- (2010) Raymond T. Bartus et al. MOVEMENT DISORDERS
- Genome editing with engineered zinc finger nucleases
- (2010) Fyodor D. Urnov et al. NATURE REVIEWS GENETICS
- Dystrophin Immunity in Duchenne's Muscular Dystrophy
- (2010) Jerry R. Mendell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients
- (2009) Edith L. Pfister et al. CURRENT BIOLOGY
- Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
- (2009) Xiaomin Su et al. HUMAN GENE THERAPY
- Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated Viruses
- (2009) Roberto Calcedo et al. JOURNAL OF INFECTIOUS DISEASES
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
- (2009) Ryan L Boudreau et al. MOLECULAR THERAPY
- Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
- (2009) C. W. Christine et al. NEUROLOGY
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
- (2009) E. Sidransky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors
- (2009) Y. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery
- (2008) Alan H. Nagahara et al. EXPERIMENTAL NEUROLOGY
- Identification and Allele-Specific Silencing of the Mutant Huntingtin Allele in Huntington's Disease Patient-Derived Fibroblasts
- (2008) P.H.J. van Bilsen et al. HUMAN GENE THERAPY
- Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease
- (2008) Payal N. Gandhi et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
- (2008) William J Marks et al. LANCET NEUROLOGY
- Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
- (2008) Jose A. Obeso et al. MOVEMENT DISORDERS
- Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain
- (2007) Julia Fuchs et al. FASEB JOURNAL
- MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector
- (2007) Yuan-Hao Chen et al. FASEB JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started